You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 73 No. 1, January 1956 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (15)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antimalarials in the Treatment of Discoid Lupus Erythematosus

Special Reference to Amodiaquin (Camoquin)

R. W. LEEPER, M.D.; M. F. ALLENDE, M.D.

AMA Arch Derm. 1956;73(1):50-57.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In recent years the effective treatment of discoid lupus erythematosus has been greatly advanced by the introduction of antimalarial drugs. While this as well as former methods of treatment remain on a purely empirical basis, awaiting fuller understanding of the pathogenesis of lupus erythematosus, it is now evident that quinacrine (Atabrine) and chloroquine (Aralen) afford suppression or control of the disease more consistently than any of the older therapeutic agents. The interesting history of the employment of antimalarials for lupus erythematosus has been recounted in several recent contributions.* Chloroquine has found acceptance as being superior to quinacrine in avoiding the undesirable skin discoloration and hematologic risks of the latter. Attention now is centered upon the investigation of other antimalarial drugs in the effort to find those which are most beneficial and at the same time least toxic.

The present report includes observations on the use of quinacrine, chloroquine, . . . [Full Text PDF of this Article]


Author Affiliations

Oakland, Calif.; San Francisco

From the Department of Medicine, Sub-Department of Dermatology and Syphilology, University of California School of Medicine, San Francisco. This study was supported by grant No. 138 from the Raschen-Tiedemann Fund.


Footnotes

Submitted for publication July 29, 1955.

Read at the California Medical Association Convention in San Francisco, May 1, 1955.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1956 American Medical Association. All Rights Reserved.